|
1
|
Pan XL, Day HW, Wang W, Beckett LA and
Schenker MB: Residential proximity to naturally occurring asbestos
and mesothelioma risk in California. Am J Respir Crit Care Med.
172:1019–1025. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kurumatani N and Kumagai S: Mapping the
risk of mesothelioma due to neighborhood asbestos exposure. Am J
Respir Crit Care Med. 178:624–629. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heintz NH, Janssen-Heininger YM and
Mossman BT: Asbestos, lung cancers, and mesotheliomas: from
molecular approaches to targeting tumor survival pathways. Am J
Respir Cell Mol Biol. 42:133–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
LaDou J, Castleman B, Frank A, et al: The
case for a global ban on asbestos. Environ Health Perspect.
118:897–901. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ueki A, Yamaguchi M, Ueki H, et al:
Polyclonal human T-cell activation by silicate in vitro.
Immunology. 82:332–335. 1994.PubMed/NCBI
|
|
6
|
Aikoh T, Tomokuni A, Matsukii T, et al:
Activation-induced cell death in human peripheral blood lymphocytes
after stimulation with silicate in vitro. Int J Oncol.
12:1355–1359. 1998.
|
|
7
|
Nishimura Y, Miura Y, Maeda M, et al:
Impairment in cytotoxicity and expression of NK cell- activating
receptors on human NK cells following exposure to asbestos fibers.
Int J Immunopathol Pharmacol. 22:579–590. 2009.
|
|
8
|
Nishimura Y, Maeda M, Kumagai N, Hayashi
H, Miura Y and Otsuki T: Decrease in phosphorylation of ERK
following decreased expression of NK cell-activating receptors in
human NK cell line exposed to asbestos. Int J Immunopathol
Pharmacol. 22:879–888. 2009.PubMed/NCBI
|
|
9
|
Kumagai-Takei N, Nishimura Y, Maeda M, et
al: Effect of asbestos exposure on differentiation of cytotoxic T
lymphocytes in mixed lymphocyte reaction of human peripheral blood
mononuclear cells. Am J Respir Cell Mol Biol. 49:28–36. 2013.
View Article : Google Scholar
|
|
10
|
Nishimura Y, Maeda M, Kumagai-Takei N, et
al: Altered functions of alveolar macrophages and NK cells involved
in asbestos-related diseases. Environ Health Prev Med. 18:198–204.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyoshi I, Kubonishi I, Yoshimoto S, et
al: Type C virus particles in a cord T-cell line derived by
co-cultivating normal human cord leukocytes and human leukaemic T
cells. Nature. 294:770–771. 1981. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maeda M, Miura Y, Nishimura Y, et al:
Immunological changes in mesothelioma patients and their
experimental detection. Clin Med Circ Respirat Pulm Med. 2:11–17.
2008.PubMed/NCBI
|
|
13
|
Hyodoh F, Takata-Tomokuni A, Miura Y, et
al: Inhibitory effects of anti-oxidants on apoptosis of a human
polyclonal T-cell line, MT-2, induced by an asbestos, chrysotile-A.
Scand J Immunol. 61:442–448. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miura Y, Nishimura Y, Katsuyama H, et al:
Involvement of IL-10 and Bcl-2 in resistance against an
asbestos-induced apoptosis of T cells. Apoptosis. 11:1825–1835.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishimura Y, Miura Y, Maeda M, et al:
Expression of the T cell receptor Vbeta repertoire in a human T
cell resistant to asbestos-induced apoptosis and peripheral blood T
cells from patients with silica and asbestos-related diseases. Int
J Immunopathol Pharmacol. 19:795–805. 2006.
|
|
16
|
Maeda M, Chen Y, Kumagai-Takei N, et al:
Alteration of cytoskeletal molecules in a human T cell line caused
by continuous exposure to chrysotile asbestos. Immunobiology.
218:1184–1191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maeda M, Yamamoto S, Chen Y, et al:
Resistance to asbestos-induced apoptosis with continuous exposure
to crocidolite on a human T cell. Sci Total Environ. 429:174–182.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maeda M, Nishimura Y, Hayashi H, et al:
Reduction of CXC chemokine receptor 3 in an in vitro model of
continuous exposure to asbestos in a human T-cell line, MT-2. Am J
Respir Cell Mol Biol. 45:470–479. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maeda M, Nishimura Y, Hayashi H, et al:
Decreased CXCR3 expression in CD4+ T cells exposed to
asbestos or derived from asbestos-exposed patients. Am J Respir
Cell Mol Biol. 795–803. 2011.
|
|
20
|
Chen S, Ishii N, Ine S, et al: Regulatory
T cell-like activity of Foxp3+ adult T cell leukemia
cells. Int Immunol. 18:269–277. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sakaguchi S, Miyara M, Costantino CM and
Hafler DA: FOXP3+ regulatory T cells in the human immune
system. Nat Rev Immunol. 10:490–500. 2010.
|
|
22
|
Flavell RA, Sanjabi S, Wrzesinski SH and
Licona-Limon P: The polarization of immune cells in the tumour
environment by TGFbeta. Nat Rev Immunol. 554–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kohyama N, Shinohara Y and Suzuki Y:
Mineral phases and some reexamined characteristics of the
International Union Against Cancer standard asbestos samples. Am J
Ind Med. 30:515–528. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brummelkamp TR, Bernards R and Agami R: A
system for stable expression of short interfering RNAs in mammalian
cells. Science. 296:550–553. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bridge AJ, Pebernard S, Ducraux A,
Nicoulaz AL and Iggo R: Induction of an interferon response by RNAi
vectors in mammalian cells. Nat Genet. 34:263–264. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Naldini L, Blomer U, Gallay P, et al: In
vivo gene delivery and stable transduction of nondividing cells by
a lentiviral vector. Science. 272:263–267. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zufferey R, Nagy D, Mandel RJ, Naldini L
and Trono D: Multiply attenuated lentiviral vector achieves
efficient gene delivery in vivo. Nat Biotechnol. 15:871–875. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arnulf B, Villemain A, Nicot C, et al:
Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta
1 signaling in human T cells via c-Jun activation: a potential
mechanism of HTLV-I leukemogenesis. Blood. 100:4129–4138. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li MO, Wan YY, Sanjabi S, Robertson AK and
Flavell RA: Transforming growth factor-beta regulation of immune
responses. Annu Rev Immunol. 24:99–146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar
|
|
31
|
Letterio JJ: TGF-beta signaling in T
cells: roles in lymphoid and epithelial neoplasia. Oncogene.
24:5701–5712. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li L, Iwamoto Y, Berezovskaya A and
Boussiotis VA: A pathway regulated by cell cycle inhibitor
p27Kip1 and checkpoint inhibitor Smad3 is involved in
the induction of T cell tolerance. Nat Immunol. 7:1157–1165. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Delisle JS, Giroux M, Boucher G, et al:
The TGF-beta-Smad3 pathway inhibits CD28-dependenT cell growth and
proliferation of CD4 T cells. Genes Immun. 14:115–126. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshimura A, Wakabayashi Y and Mori T:
Cellular and molecular basis for the regulation of inflammation by
TGF-beta. J Biochem. 147:781–792. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu H, Kavsak P, Abdollah S, Wrana JL and
Thomsen GH: A SMAD ubiquitin ligase targets the BMP pathway and
affects embryonic pattern formation. Nature. 400:687–693. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wrzesinski SH, Wan YY and Flavell RA:
Transforming growth factor-beta and the immune response:
implications for anticancer therapy. Clin Cancer Res. 13:5262–5270.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Suzuki E, Kim S, Cheung HK, et al: A novel
small-molecule inhibitor of transforming growth factor beta type I
receptor kinase (SM16) inhibits murine mesothelioma tumor growth in
vivo and prevents tumor recurrence after surgical resection. Cancer
Res. 67:2351–2359. 2007. View Article : Google Scholar
|
|
38
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fujii M, Toyoda T, Nakanishi H, et al:
TGF-beta synergizes with defects in the Hippo pathway to stimulate
human malignant mesothelioma growth. J Exp Med. 209:479–494. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Murakami S, Nishimura Y, Maeda M, et al:
Cytokine alteration and speculated immunological pathophysiology in
silicosis and asbestos-related diseases. Environ Health Prev Med.
14:216–222. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brown KA, Pietenpol JA and Moses HL: A
tale of two proteins: differential roles and regulation of Smad2
and Smad3 in TGF-beta signaling. J Cell Biochem. 101:9–33. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Siegel PM and Massague J: Cytostatic and
apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev
Cancer. 3:807–821. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Levy L and Hill CS: Alterations in
components of the TGF-beta superfamily signaling pathways in human
cancer. Cytokine Growth Factor Rev. 17:41–58. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xiao YQ, Freire-de-Lima CG, Schiemann WP,
Bratton DL, Vandivier RW and Henson PM: Transcriptional and
translational regulation of TGF-beta production in response to
apoptotic cells. J Immunol. 181:3575–3585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Huber S, Schrader J, Fritz G, et al: P38
MAP kinase signaling is required for the conversion of
CD4+CD25− T cells into iTreg. PLoS One.
3:e33022008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Calabro L, Morra A, Fonsatti E, et al:
Tremelimumab for patients with chemotherapy-resistant advanced
malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Lancet Oncol. 14:1104–1111. 2013. View Article : Google Scholar : PubMed/NCBI
|
